Maria Jose Pozuelo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Jose Pozuelo has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Lalueza
12 de Octubre University Hospital, Research Institute of Hospital 12 de Octubre (imas+12), Complutense University
1 shared publication - Estanislao Nistal-Villan
Microbiology Section, Dpto. Ciencias (CC), Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, Spain
1 shared publication - Iván Sanz-Muñoz
National Influenza Centre, Hospital Clinico Universitario de Valladolid
1 shared publication - Javier Arranz-Herrero
Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA) Nemesio Díez, Medicine Faculty, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660 Boadilla del Monte, Spain
1 shared publication - Jesús Presa
Independent researcher, 28003 Madrid, Spain
1 shared publication - Jordi Ochando
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
1 shared publication
Latest Publications
- Open Access
- 8 January 2025
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 34 (175) , 240144
Influenza vaccine outcomes: a meta-analysis revealing morbidity benefits amid low infection prevention
Background: The morbidity and mortality associated with influenza viruses are a significant public health challenge. Annual vaccination against circulating influenza strains reduces hospitalisations and increases survival rates but requires a yearly redesign of vaccines against prevalent subtypes. The complex genetics of influenza viruses with high antigenic drift create an ongoing challenge in vaccine development to address dynamic influenza epidemiology. Understanding the evolution of influenza viruses and the vaccine's effectiveness against different types and subtypes is pivotal to designing public health measures against influenza.Methods: We conducted a systematic review and meta-analysis of 192 705 patients, collecting information on the incidence and severity of the disease. The results of this meta-analysis were further validated using data from 6 594 765 patients from TriNetX. We analysed the prevalence of the most common influenza A virus (IAV) subtypes (H1N1 and H3N2) and influenza B virus (IBV), as well as vaccination effectiveness against them in three age groups, given that age is associated with influenza disease severity.Results: Our analysis reflects that overall vaccination against H1N1 IAV and IBV is effective in reducing infection and influenza-related complications in children aged 65 years old. By contrast, while vaccination against H3N2 IAV is effective in protecting against infection in infants e.g.hospitalisations, mortality and disease severity; for improving vaccine formulations and public awareness; and for enhancing vaccination campaigns to improve coverage and public acceptance.
- 8 January 2025
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 34 (175) , 240144
Open AccessInfluenza vaccine outcomes: a meta-analysis revealing morbidity benefits amid low infection prevention
Background: The morbidity and mortality associated with influenza viruses are a significant public health challenge. Annual vaccination against circulating influenza strains reduces hospitalisations and increases survival rates but requires a yearly redesign of vaccines against prevalent subtypes. The complex genetics of influenza viruses with high antigenic drift create an ongoing challenge in vaccine development to address dynamic influenza epidemiology. Understanding the evolution of influenza viruses and the vaccine's effectiveness against different types and subtypes is pivotal to designing public health measures against influenza.Methods: We conducted a systematic review and meta-analysis of 192 705 patients, collecting information on the incidence and severity of the disease. The results of this meta-analysis were further validated using data from 6 594 765 patients from TriNetX. We analysed the prevalence of the most common influenza A virus (IAV) subtypes (H1N1 and H3N2) and influenza B virus (IBV), as well as vaccination effectiveness against them in three age groups, given that age is associated with influenza disease severity.Results: Our analysis reflects that overall vaccination against H1N1 IAV and IBV is effective in reducing infection and influenza-related complications in children aged 65 years old. By contrast, while vaccination against H3N2 IAV is effective in protecting against infection in infants e.g.hospitalisations, mortality and disease severity; for improving vaccine formulations and public awareness; and for enhancing vaccination campaigns to improve coverage and public acceptance.